Imperial College London
Portrait Picture

Prof Liz Lightstone

Faculty of Medicine, Department of Immunology and Inflammation

Proconsul and Professor of Renal Medicine
 
 
 
//

Contact

 

+44 (0)20 3313 3152l.lightstone Website CV

 
 
//

Assistant

 

Miss Anjli Jagpal +44 (0)20 3313 3152

 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Prendecki:2021:10.1136/annrheumdis-2021-220626,
author = {Prendecki, M and Clarke, C and Edwards, H and McIntyre, S and Mortimer, P and Gleeson, S and Martin, P and Thomson, T and Randell, P and Shah, A and Singanayagam, A and Lightstone, L and Cox, A and Kelleher, P and Willicombe, M and McAdoo, SP},
doi = {10.1136/annrheumdis-2021-220626},
journal = {Annals of the Rheumatic Diseases},
pages = {1322--1329},
title = {Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.},
url = {http://dx.doi.org/10.1136/annrheumdis-2021-220626},
volume = {80},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - OBJECTIVE: There is an urgent need to assess the impact of immunosuppressive therapies on the immunogenicity and efficacy of SARS-CoV-2 vaccination. METHODS: Serological and T-cell ELISpot assays were used to assess the response to first-dose and second-dose SARS-CoV-2 vaccine (with either BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccines) in 140 participants receiving immunosuppression for autoimmune rheumatic and glomerular diseases. RESULTS: Following first-dose vaccine, 28.6% (34/119) of infection-naïve participants seroconverted and 26.0% (13/50) had detectable T-cell responses to SARS-CoV-2. Immune responses were augmented by second-dose vaccine, increasing seroconversion and T-cell response rates to 59.3% (54/91) and 82.6% (38/46), respectively. B-cell depletion at the time of vaccination was associated with failure to seroconvert, and tacrolimus therapy was associated with diminished T-cell responses. Reassuringly, only 8.7% of infection-naïve patients had neither antibody nor T-cell responses detected following second-dose vaccine. In patients with evidence of prior SARS-CoV-2 infection (19/140), all mounted high-titre antibody responses after first-dose vaccine, regardless of immunosuppressive therapy. CONCLUSION: SARS-CoV-2 vaccines are immunogenic in patients receiving immunosuppression, when assessed by a combination of serology and cell-based assays, although the response is impaired compared with healthy individuals. B-cell depletion following rituximab impairs serological responses, but T-cell responses are preserved in this group. We suggest that repeat vaccine doses for serological non-responders should be investigated as means to induce more robust immunological response.
AU  - Prendecki,M
AU  - Clarke,C
AU  - Edwards,H
AU  - McIntyre,S
AU  - Mortimer,P
AU  - Gleeson,S
AU  - Martin,P
AU  - Thomson,T
AU  - Randell,P
AU  - Shah,A
AU  - Singanayagam,A
AU  - Lightstone,L
AU  - Cox,A
AU  - Kelleher,P
AU  - Willicombe,M
AU  - McAdoo,SP
DO  - 10.1136/annrheumdis-2021-220626
EP  - 1329
PY  - 2021///
SN  - 0003-4967
SP  - 1322
TI  - Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
T2  - Annals of the Rheumatic Diseases
UR  - http://dx.doi.org/10.1136/annrheumdis-2021-220626
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34362747
UR  - https://ard.bmj.com/content/80/10/1322
UR  - http://hdl.handle.net/10044/1/91658
VL  - 80
ER  -
Download